Clinical Trials for Multiple Sclerosis
Multiple sclerosis (MS) is a condition in which the immune system attacks the myelin sheath -- the protective coating around nerve fibers -- disrupting signals between the brain and body. It can cause fatigue, vision problems, mobility challenges, and cognitive changes. Treatment has transformed dramatically over the past two decades, largely because of clinical trials that brought new disease-modifying therapies to market.
That research continues. If you have MS and are not achieving adequate control on your current therapy, or if your insurance has denied a medication your neurologist recommends, clinical trials may offer a meaningful path forward.
According to the National Multiple Sclerosis Society, approximately 1 million people in the United States live with MS.
What Types of Trials Are Available?
Phase 3 trials for relapsing MS are studying newer high-efficacy therapies, including BTK inhibitors -- a class that has shown significant promise and represents one of the most active areas of MS research. Progressive MS trials are studying treatments for primary progressive MS (PPMS) and secondary progressive MS (SPMS), which historically had fewer options. Ocrelizumab (Ocrevus) opened this door for PPMS; trials are now exploring additional agents. Remyelination trials study whether the myelin damaged by MS can be repaired. These early-phase trials represent a frontier in MS research. Biomarker and observational studies are working to improve how MS is diagnosed, monitored, and understood over time.Search ClinicalTrials.gov for currently recruiting MS trials.
Am I Eligible?
Common factors that affect MS trial eligibility:
- Your MS type (relapsing-remitting, primary progressive, secondary progressive)
- Current and prior disease-modifying therapy history
- MRI findings showing active or stable disease
- EDSS score (a standardized measure of disability) -- many trials have EDSS cutoffs
- Time since last relapse or disease progression event
- No recent use of certain immunosuppressants that could affect trial results
Some trials specifically look for people who are not adequately controlled on current therapy. Others enroll people who are switching from one therapy class to another.
Your neurologist is the essential guide here. Talk to your doctor before making any decisions about your treatment.
What If My Insurance Denied My Medication?
High-efficacy MS therapies like ocrelizumab (Ocrevus), natalizumab (Tysabri), and fingolimod (Gilenya) are among the most frequently denied specialty medications. Step therapy requirements often force people to try older, lower-efficacy drugs before insurers will cover newer options -- a practice that many neurologists argue puts patients at risk.
If your neurologist has recommended a high-efficacy therapy and your insurance has denied it, you can appeal. A compelling letter from your neurologist explaining why a lower-efficacy starting point is not appropriate for your specific situation can carry significant weight. While your appeal proceeds, a clinical trial studying a similar or newer mechanism may offer access to treatment.
Read more: Denied Ocrevus -- clinical trial options | Denied Tysabri -- clinical trial options
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Are clinical trials for multiple sclerosis free?
In most cases, yes. Trial sponsors (pharmaceutical companies, universities, or the NIH) cover the cost of the experimental treatment. You may still have costs for routine care — like doctor visits or standard tests — depending on your insurance. Always ask the trial coordinator what costs you might be responsible for before enrolling.
How do I find multiple sclerosis trials near me?
The best place to start is ClinicalTrials.gov, the official registry of all trials in the US. Search by condition name and filter by your location. Your specialist can also help identify trials at academic medical centers in your region.
Can I join a trial after being denied Ocrevus or Tysabri?
Yes, and in many cases a denial can actually make you a stronger candidate — trials often enroll patients who have not responded to or cannot access standard treatments. Talk to your doctor about whether your denial history makes you eligible for open trials studying Ocrevus or Tysabri or similar medications.